Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfu043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trophoblast-derived factors drive human mesenchymal stem cell differentiation along an endothelial lineage: A model of early placental vasculogenesis.
Reprod Biol
January 2025
Department of Biology, Edge Hill University, L39 4QP, UK. Electronic address:
Mechanisms controlling the process and patterning of blood vessel development in the placenta remain largely unknown. The close physical proximity of early blood vessels observed in the placenta and the cytotrophoblast, as well as the reported production of vasculogenic growth factors by the latter, suggests that signalling between these two niches may be important. Here, we have developed an in vitro model to address the hypothesis that the cytotrophoblast, by the secretion of soluble factors, drives differentiation of resident sub-trophoblastic mesenchymal stem cells (MSCs) along a vascular lineage, thereby establishing feto-placental circulation.
View Article and Find Full Text PDFPreeclampsia Treatment Aspirin/Clampsilin: Oxidative Stress, sFlt-1/PIGF Soluble Tyrosine Kinase 1, and Placental Growth Factor Monitoring.
Int J Mol Sci
December 2024
Department of Medical Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria.
The present study aimed to investigate and compare oxidative stress biomarkers and antioxidant enzyme activity in the serum of women at risk of developing preeclampsia (PE) to prevent adverse pregnancy outcomes through early intervention. Changes in soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) levels were measured between 11 and 13 gestational weeks (gw.) before the onset of preeclampsia and its associated complications.
View Article and Find Full Text PDFCan maternal serum soluble fms-like tyrosine kinase-1 to placental growth factor levels at term anticipate adverse pregnancy outcomes?
J Obstet Gynaecol Res
January 2025
Pregnancy Research Centre, Department of Maternal Fetal Medicine, the Royal Women's Hospital, Parkville, Victoria, Australia.
Aim: To evaluate if maternal serum soluble fms-like tyrosine kinase-1(sFlt-1) to placental growth factor (PlGF) ratio levels at term can anticipate the following adverse pregnancy outcomes: small for gestational age neonates; operative delivery for suspected fetal welfare compromise; and neonatal compromise.
Methods: A retrospective analysis of a single hospital database containing antenatal soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1/PlGF) ratio results together with associated demographic, clinical and investigative information. Subjects with antenatal sFlt-1/PlGF measurements taken ≥37 weeks' gestation were analyzed.
Distinct phenotypes in the preeclamptic-like mouse model induced by adenovirus carrying sFlt1 and recombinant sFlt1 protein.
Eur J Med Res
December 2024
Clinical and Translational Research Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Background: Preeclampsia (PE) is a pregnancy-specific, multisystemic disorder that affects 2-8% pregnancies worldwide and is a leading cause of maternal and perinatal mortality. At present, there is no cure for PE apart from delivery the placenta. Therefore, it is important and urgent to possess a suitable animal model to study the pathology and treatment of PE.
View Article and Find Full Text PDFFirst-Trimester Soluble fms-like Tyrosine Kinase 1 (sFlt-1) for the Prediction of Preterm Preeclampsia.
J Obstet Gynaecol Can
December 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, Québec, QC; Centre de recherche du CHU de Québec - Université Laval, Québec, QC. Electronic address:
While soluble fms-like tyrosine kinase 1 (sFlt-1) is used to predict preeclampsia (PE) and its severity in late pregnancy, we aimed to clarify its role in early pregnancy. Using prospective cohorts, we estimated the association between sFlt-1, adjusted for gestational age, and preterm PE. sFlt-1 was significantly decreased in the first trimester, mostly before the 13th week, and significantly increased in the third trimester in those who developed preterm PE and particularly early-onset PE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!